Market Place
Sourcing Support
Pharvaris Reports 2024 Financial Results and Business Update
07 Apr 2025 //
GLOBENEWSWIRE
Pharvaris: Orphan Designation Granted to Deucrictibant by EU
01 Apr 2025 //
GLOBENEWSWIRE
Pharvaris To Present At Leerink Partners 2025 Conference
03 Mar 2025 //
GLOBENEWSWIRE
Pharvaris Shows Long-Term Deucrictibant Data At AAAAI/WAO 2025
03 Mar 2025 //
GLOBENEWSWIRE
Pharvaris Outlines 2025 Strategic Priorities
13 Jan 2025 //
GLOBENEWSWIRE
Pharvaris Reports Q3 2024 Results & Business Updates
13 Nov 2024 //
GLOBENEWSWIRE
Pharvaris to Participate in Guggenheim Healthcare Conference
12 Nov 2024 //
GLOBENEWSWIRE
Pharvaris Presents HAE Data At ACAAI Annual Meeting
24 Oct 2024 //
GLOBENEWSWIRE
Pharvaris Presents Data On Deucrictibant For HAE At Meetings
16 Oct 2024 //
GLOBENEWSWIRE
Pharvaris to Host Virtual Investor Event on October 23, 2024
15 Oct 2024 //
GLOBENEWSWIRE
Pharvaris To Present HAE Treatment Data At HAEi Workshop
03 Oct 2024 //
GLOBENEWSWIRE
Pharvaris Presents Data at the Bradykinin Symposium 2024
05 Sep 2024 //
GLOBENEWSWIRE
Pharvaris Presents Deucrictibant Data At Bradykinin Symposium
05 Sep 2024 //
GLOBENEWSWIRE
Pharvaris Provides Business Update And Expands Program
05 Sep 2024 //
GLOBENEWSWIRE
Pharvaris Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Pharvaris Announces Annual Meeting of Shareholders
11 Jun 2024 //
GLOBENEWSWIRE
Pharvaris: Deucrictibant Data Highlights At Recent Conferences
04 Jun 2024 //
GLOBENEWSWIRE
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
13 May 2024 //
GLOBENEWSWIRE
Pharvaris Q1 2024 Financials, Business Update
08 May 2024 //
GLOBENEWSWIRE
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
10 Apr 2024 //
GLOBENEWSWIRE
Pharvaris Reports Q4 and Full-Year 2023 Financial Results
10 Apr 2024 //
GLOBENEWSWIRE
Pharvaris to Present Deucrictibant Data at the CIIC Spring 2024 Conference
04 Apr 2024 //
GLOBENEWSWIRE
Pharvaris Announces Phase 3 Clinical Study Design
18 Mar 2024 //
GLOBENEWSWIRE
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
06 Mar 2024 //
GLOBENEWSWIRE
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
05 Mar 2024 //
GLOBENEWSWIRE
Positive Results from Phase 2 of Deucrictibant for HAE Attacks to be Presented
22 Feb 2024 //
GLOBENEWSWIRE
Pharvaris Announces Extraordinary Meeting of Shareholders
16 Feb 2024 //
GLOBENEWSWIRE
Pharvaris to Present at the WSAAI Annual Meeting 2024
26 Jan 2024 //
GLOBENEWSWIRE
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant
22 Jan 2024 //
GLOBENEWSWIRE
FDA lifts remaining hold on Pharvaris’ HAE drug
22 Jan 2024 //
FIERCE BIOTECH
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
05 Jan 2024 //
GLOBENEWSWIRE
Pharvaris Presents Data for Trials of On-demand Treatment of HAE
08 Dec 2023 //
GLOBENEWSWIRE
Pharvaris Announces Positive Top-line Phase 2 Data of Deucrictibant
06 Dec 2023 //
GLOBENEWSWIRE
Pharvaris Announces Pricing of $300M Underwritten Offering of Ordinary Shares
06 Dec 2023 //
GLOBENEWSWIRE
Pharvaris to Present at the GA²LEN UCARE Conference 2023
30 Nov 2023 //
PRESS RELEASE
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
15 Nov 2023 //
GLOBENEWSWIRE
Pharvaris Presents Deucrictibant Data HAE Treatment Satisfaction Data
09 Nov 2023 //
GLOBENEWSWIRE
Pharvaris Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
30 Oct 2023 //
PRESS RELEASE
Pharvaris To Present at the APAAACI 2023 International Conference
13 Oct 2023 //
GLOBENEWSWIRE
Pharvaris To Present at the CIIC Fall 2023 Conference
04 Oct 2023 //
GLOBENEWSWIRE
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
19 Sep 2023 //
GLOBENEWSWIRE
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Pharvaris To Present at the 18th German Allergy Congress
06 Sep 2023 //
GLOBENEWSWIRE
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
23 Aug 2023 //
GLOBENEWSWIRE
Pharvaris Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
21 Jul 2023 //
GLOBENEWSWIRE
Why Shares of Pharvaris N.V. Are Up Tuesday
27 Jun 2023 //
FOOL
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant
26 Jun 2023 //
GLOBENEWSWIRE
Pharvaris Announces $70 Million Private Placement Financing
20 Jun 2023 //
GLOBENEWSWIRE
Data of Deucrictibant for Treatment of HAE Attacks Presented at the EAACI
10 Jun 2023 //
GLOBENEWSWIRE
Pharvaris Announces Annual Meeting of Shareholders
01 Jun 2023 //
GLOBENEWSWIRE
Pharvaris Reports 1Q 2023 FYR and Provides Business Update
08 May 2023 //
GLOBENEWSWIRE
Deucrictibant Data Highlighted in Multiple at C1-Inhibitor Deficiency
06 May 2023 //
GLOBENEWSWIRE
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results
05 Apr 2023 //
GLOBENEWSWIRE
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for HAE Attacks
18 Mar 2023 //
GLOBENEWSWIRE
Pharvaris to Present in Upcoming March Investor Conferences
02 Mar 2023 //
GLOBENEWSWIRE
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416
24 Feb 2023 //
GLOBENEWSWIRE
Pharvaris to Present at SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
